Cargando…

Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry

INTRODUCTION: Ocrelizumab is a monoclonal anti-CD20 antibody approved for the treatment of multiple sclerosis (MS). The clinical value of therapeutic drug monitoring (TDM) for this antibody in treatment of MS is unknown, and an adequately specific and precise quantitation method for ocrelizumab in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hallin, Erik I., Trætteberg Serkland, Trond, Myhr, Kjell-Morten, Grytten Torkildsen, Øivind, Skrede, Silje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334332/
https://www.ncbi.nlm.nih.gov/pubmed/35910410
http://dx.doi.org/10.1016/j.jmsacl.2022.07.004
_version_ 1784759081532129280
author Hallin, Erik I.
Trætteberg Serkland, Trond
Myhr, Kjell-Morten
Grytten Torkildsen, Øivind
Skrede, Silje
author_facet Hallin, Erik I.
Trætteberg Serkland, Trond
Myhr, Kjell-Morten
Grytten Torkildsen, Øivind
Skrede, Silje
author_sort Hallin, Erik I.
collection PubMed
description INTRODUCTION: Ocrelizumab is a monoclonal anti-CD20 antibody approved for the treatment of multiple sclerosis (MS). The clinical value of therapeutic drug monitoring (TDM) for this antibody in treatment of MS is unknown, and an adequately specific and precise quantitation method for ocrelizumab in patient serum could facilitate investigation. Liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based quantitation methods have been shown to have higher analytic specificity and precision than enzyme-linked immunosorbent assays. OBJECTIVES: To establish and validate an LC-MS/MS-based quantitation method for ocrelizumab. METHODS: We present an LC-MS/MS-based quantitation method using immunocapture purification followed by trypsinization and analysis by a triple quadrupole mass analyzer obtaining results within the same day. RESULTS: We found that the ocrelizumab peptide GLEWVGAIYPGNGDTSYNQK (Q1/Q3 Quantifier ion: 723.68(3+)/590.77 y11(2+) Qualifier ion: 723.68(3+)/672.30 y12(2+)) can be used for quantitation and thereby developed a method for quantifying ocrelizumab in human serum with a quantitation range of 1.56 to 200 µg/mL. The method was validated in accordance with EMA requirements in terms of selectivity, carry-over, lower limit of quantitation, calibration curve, accuracy, precision and matrix effect. Ocrelizumab serum concentrations were measured in three MS patients treated with ocrelizumab, immediately before and after ocrelizumab infusion, with additional sampling after 2, 4, 8 and 12 weeks. Measured serum concentrations of ocrelizumab showed expected values for both Cmax and drug half-life over the sampled time period. CONCLUSION: We have established a reliable quantitation method for serum ocrelizumab that can be applied in clinical studies, facilitating the evaluation of ocrelizumab TDM in MS.
format Online
Article
Text
id pubmed-9334332
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93343322022-07-30 Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry Hallin, Erik I. Trætteberg Serkland, Trond Myhr, Kjell-Morten Grytten Torkildsen, Øivind Skrede, Silje J Mass Spectrom Adv Clin Lab Regular Article INTRODUCTION: Ocrelizumab is a monoclonal anti-CD20 antibody approved for the treatment of multiple sclerosis (MS). The clinical value of therapeutic drug monitoring (TDM) for this antibody in treatment of MS is unknown, and an adequately specific and precise quantitation method for ocrelizumab in patient serum could facilitate investigation. Liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based quantitation methods have been shown to have higher analytic specificity and precision than enzyme-linked immunosorbent assays. OBJECTIVES: To establish and validate an LC-MS/MS-based quantitation method for ocrelizumab. METHODS: We present an LC-MS/MS-based quantitation method using immunocapture purification followed by trypsinization and analysis by a triple quadrupole mass analyzer obtaining results within the same day. RESULTS: We found that the ocrelizumab peptide GLEWVGAIYPGNGDTSYNQK (Q1/Q3 Quantifier ion: 723.68(3+)/590.77 y11(2+) Qualifier ion: 723.68(3+)/672.30 y12(2+)) can be used for quantitation and thereby developed a method for quantifying ocrelizumab in human serum with a quantitation range of 1.56 to 200 µg/mL. The method was validated in accordance with EMA requirements in terms of selectivity, carry-over, lower limit of quantitation, calibration curve, accuracy, precision and matrix effect. Ocrelizumab serum concentrations were measured in three MS patients treated with ocrelizumab, immediately before and after ocrelizumab infusion, with additional sampling after 2, 4, 8 and 12 weeks. Measured serum concentrations of ocrelizumab showed expected values for both Cmax and drug half-life over the sampled time period. CONCLUSION: We have established a reliable quantitation method for serum ocrelizumab that can be applied in clinical studies, facilitating the evaluation of ocrelizumab TDM in MS. Elsevier 2022-07-22 /pmc/articles/PMC9334332/ /pubmed/35910410 http://dx.doi.org/10.1016/j.jmsacl.2022.07.004 Text en © 2022 THE AUTHORS https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Regular Article
Hallin, Erik I.
Trætteberg Serkland, Trond
Myhr, Kjell-Morten
Grytten Torkildsen, Øivind
Skrede, Silje
Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry
title Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry
title_full Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry
title_fullStr Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry
title_full_unstemmed Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry
title_short Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry
title_sort ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334332/
https://www.ncbi.nlm.nih.gov/pubmed/35910410
http://dx.doi.org/10.1016/j.jmsacl.2022.07.004
work_keys_str_mv AT hallineriki ocrelizumabquantitationbyliquidchromatographytandemmassspectrometry
AT trættebergserklandtrond ocrelizumabquantitationbyliquidchromatographytandemmassspectrometry
AT myhrkjellmorten ocrelizumabquantitationbyliquidchromatographytandemmassspectrometry
AT gryttentorkildsenøivind ocrelizumabquantitationbyliquidchromatographytandemmassspectrometry
AT skredesilje ocrelizumabquantitationbyliquidchromatographytandemmassspectrometry